» Articles » PMID: 19153271

Long-term Effects of Enzyme Replacement Therapy on Fabry Cardiomyopathy: Evidence for a Better Outcome with Early Treatment

Overview
Journal Circulation
Date 2009 Jan 21
PMID 19153271
Citations 173
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Enzyme replacement therapy with recombinant alpha-galactosidase A reduces left ventricular hypertrophy and improves regional myocardial function in patients with Fabry disease during short-term treatment. Whether enzyme replacement therapy is effective in all stages of Fabry cardiomyopathy during long-term follow-up is unknown.

Methods And Results: We studied 32 Fabry patients over a period of 3 years regarding disease progression and clinical outcome under enzyme replacement therapy. Regional myocardial fibrosis was assessed by magnetic resonance imaging late-enhancement technique. Echocardiographic myocardial mass was calculated with the Devereux formula, and myocardial function was quantified by ultrasonic strain-rate imaging. In addition, exercise capacity was measured by bicycle stress test. All measurements were repeated at yearly intervals. At baseline, 9 patients demonstrated at least 2 fibrotic left ventricular segments (severe myocardial fibrosis), 11 had 1 left ventricular segment affected (mild fibrosis), and 12 were without fibrosis. In patients without fibrosis, enzyme replacement therapy resulted in a significant reduction in left ventricular mass (238+/-42 g at baseline, 202+/-46 g at 3 years; P for trend <0.001), an improvement in myocardial function (systolic radial strain rate, 2.3+/-0.4 and 2.9+/-0.6 seconds(-1), respectively; P for trend=0.045), and a higher exercise capacity obtained by bicycle stress exercise (106+/-14 and 122+/-26 W, respectively; P for trend=0.014). In contrast, patients with mild or severe fibrosis showed a minor reduction in left ventricular hypertrophy and no improvement in myocardial function or exercise capacity.

Conclusions: These data suggest that treatment of Fabry cardiomyopathy with recombinant alpha-galactosidase A should best be started before myocardial fibrosis has developed to achieve long-term improvement in myocardial morphology and function and exercise capacity.

Citing Articles

A systematic literature review to evaluate the cardiac and cerebrovascular outcomes of patients with Fabry disease treated with agalsidase Beta.

Oudit G, DasMahapatra P, Lyn N, Wilson F, Adeyemi A, Lee C Front Cardiovasc Med. 2025; 11:1415547.

PMID: 39906339 PMC: 11790562. DOI: 10.3389/fcvm.2024.1415547.


Anderson-Fabry Disease: An Overview of Current Diagnosis, Arrhythmic Risk Stratification, and Therapeutic Strategies.

Tognola C, Ruzzenenti G, Maloberti A, Varrenti M, Mazzone P, Giannattasio C Diagnostics (Basel). 2025; 15(2.

PMID: 39857023 PMC: 11763368. DOI: 10.3390/diagnostics15020139.


Hemodynamics in Left-Sided Cardiomyopathies.

Monaco G, Amata F, Battaglia V, Panico C, Condorelli G, Pinto G Rev Cardiovasc Med. 2025; 25(12):455.

PMID: 39742240 PMC: 11683717. DOI: 10.31083/j.rcm2512455.


Impact of enzyme replacement therapy on clinical manifestations in females with Fabry disease.

Lenders M, Nowak A, Cybulla M, Kaufeld J, Kohn A, Muschol N Orphanet J Rare Dis. 2024; 19(1):490.

PMID: 39731156 PMC: 11673826. DOI: 10.1186/s13023-024-03503-4.


Overcoming Resistance in Anderson-Fabry Disease: Current Therapeutic Challenges and Future Perspectives.

Carella M, Forleo C, Caretto P, Naccarati M, Dentamaro I, Dicorato M J Clin Med. 2024; 13(23).

PMID: 39685654 PMC: 11641994. DOI: 10.3390/jcm13237195.